Diwakar Davar, Associate Professor, Clinical Director, Melanoma and Skin Cancer Program at UPMC Hillman Cancer Center, shared a post on X:
“3 new Nature Medicine trials show FMT can boost ICI activity across tumors:
- TACITO – mRCC PFS benefit
- PERFORM – encapsulated FMT + ICI feasibility
- FMT-LUMINate – ORR 80% NSCLC, 75% melanoma
Microbiome engineering is entering oncology.”
Title: Microbiome modulation in cancer immunotherapy
Authors: Sumanta K. Pal, Diwakar Davar
Read the Full Article.
Other articles from Nature Medicine on OncoDaily.
